{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:52:52Z","timestamp":1774288372272,"version":"3.50.1"},"reference-count":310,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>We conducted a comprehensive review of the current literature of published data, clinical trials (MEDLINE; ncbi.pubmed.com), congress contributions (asco.org; esmo.org), and active recruiting clinical trains (clinicaltrial.gov) on targeted therapies in cholangiocarcinoma. Palliative treatment regimens were analyzed as well as preoperative and perioperative treatment options. We summarized the current knowledge for each mutation and molecular pathway that is or has been under clinical evaluation and discussed the results on the background of current treatment guidelines. We established and recommended targeted treatment options that already exist for second-line settings, including IDH-, BRAF-, and NTRK-mutated tumors, as well as for FGFR2 fusion, HER2\/neu-overexpression, and microsatellite instable tumors. Other options for targeted treatment include EGFR- or VEGF-dependent pathways, which are known to be overexpressed or dysregulated in this cancer type and are currently under clinical investigation. Targeted therapy in CCA is a hallmark of individualized medicine as these therapies aim to specifically block pathways that promote cancer cell growth and survival, leading to tumor shrinkage and improved patient outcomes based on the molecular profile of the tumor.<\/jats:p>","DOI":"10.3390\/cancers16091690","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T09:26:02Z","timestamp":1714123562000},"page":"1690","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma"],"prefix":"10.3390","volume":"16","author":[{"given":"Philipp","family":"Heumann","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases University Hospital Regensburg Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Albert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases University Hospital Regensburg Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"G\u00fclow","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases University Hospital Regensburg Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"T\u00fcmen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases University Hospital Regensburg Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases University Hospital Regensburg Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Kandulski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases University Hospital Regensburg Franz-Josef-Strau\u00df-Allee 11, 93053 Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of Hepatocellular Carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma\u2014Evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17588359231163785","DOI":"10.1177\/17588359231163785","article-title":"Adjuvant therapy of biliary tract cancers","volume":"15","author":"Kefas","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1055\/a-1589-7585","article-title":"S3-Leitlinie: Diagnostik und Therapie des hepatozellul\u00e4ren Karzinoms und bili\u00e4rer Karzinome\u2014Version 2.0\u2014Juni 2021, AWMF-Registernummer: 032-053OL","volume":"60","author":"Voesch","year":"2022","journal-title":"Z. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2012.02.022","article-title":"Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma","volume":"57","author":"Palmer","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/jnci\/djz103","article-title":"Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies","volume":"111","author":"McGee","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24351","article-title":"Risk factors for cholangiocarcinoma","volume":"54","author":"Tyson","year":"2011","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e0186643","DOI":"10.1371\/journal.pone.0186643","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare","volume":"12","author":"Petrick","year":"2017","journal-title":"PLoS ONE"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e0133128","DOI":"10.1371\/journal.pone.0133128","article-title":"Cancer Attributable to Asbestos Exposure in Shipbreaking Workers: A Matched-Cohort Study","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/bjs.4815","article-title":"Bile duct cysts in adults","volume":"91","author":"Havnen","year":"2004","journal-title":"Br. J. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis","volume":"72","author":"Clements","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.cgh.2007.05.020","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based case-control study","volume":"5","author":"Welzel","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.3748\/wjg.v26.i31.4718","article-title":"Risk of malignancy in Caroli disease and syndrome: A systematic review","volume":"26","author":"Fahrner","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1053\/j.gastro.2004.12.048","article-title":"Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study","volume":"128","author":"Shaib","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ijc.22283","article-title":"Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: A nationwide case-control study","volume":"120","author":"Welzel","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.7314\/APJCP.2014.15.8.3477","article-title":"Inflammatory bowel disease and risk of cholangiocarcinoma: Evidence from a meta-analysis of population-based studies","volume":"15","author":"Huai","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1572-0241.2007.01104.x","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A hospital-based case-control study","volume":"102","author":"Shaib","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1023\/A:1013747228572","article-title":"Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: A case-control study in Italy","volume":"12","author":"Donato","year":"2001","journal-title":"Cancer Causes Control"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/j.1572-0241.2008.01796.x","article-title":"Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: A case-control study","volume":"103","author":"Lee","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3748\/wjg.14.632","article-title":"Risk factors for intrahepatic cholangiocarcinoma: A case-control study in China","volume":"14","author":"Zhou","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.22606","article-title":"Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans","volume":"49","author":"Engels","year":"2009","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1349-7006.2004.tb02492.x","article-title":"Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma","volume":"95","author":"Yamamoto","year":"2004","journal-title":"Cancer Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00268-003-7246-7","article-title":"Management of biliary and duodenal complications of chronic pancreatitis","volume":"27","author":"Vijungco","year":"2003","journal-title":"World J. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00004836-200304000-00015","article-title":"Risk of cancer in patients hospitalized with fatty liver: A Danish cohort study","volume":"36","author":"Mellemkjaer","year":"2003","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10654-009-9365-4","article-title":"Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: A national cohort study, 1978\u20132003","volume":"24","author":"Erichsen","year":"2009","journal-title":"Eur. J. Epidemiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41395-018-0207-4","article-title":"Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis","volume":"113","author":"Petrick","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/CEJ.0b013e3283481d89","article-title":"Diabetes mellitus and increased risk of cholangiocarcinoma: A meta-analysis","volume":"21","author":"Jing","year":"2012","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_34","first-page":"474","article-title":"Hemochromatosis and hilar cholangiocarcinoma: Report of a case","volume":"92","year":"2000","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jss.2012.10.051","article-title":"Intrahepatic cholangiocarcinoma: Impact of genetic hemochromatosis on outcome and overall survival after surgical resection","volume":"180","author":"Sulpice","year":"2013","journal-title":"J. Surg. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1309\/2RFK-HD06-A788-1FJH","article-title":"Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum","volume":"116","author":"Morcos","year":"2001","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0140-6736(15)60313-0","article-title":"Clonorchiasis","volume":"387","author":"Qian","year":"2016","journal-title":"Lancet"},{"key":"ref_38","first-page":"605","article-title":"Risk Factors for Cholangiocarcinoma in Thailand: A Systematic Review and Meta-Analysis","volume":"19","author":"Luvira","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S2214-109X(16)30301-1","article-title":"Global burden of cancers attributable to liver flukes","volume":"5","author":"Qian","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12876-017-0696-4","article-title":"Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: A systematic review and meta-analysis","volume":"17","author":"Wongjarupong","year":"2017","journal-title":"BMC Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhep.2008.08.013","article-title":"High lifetime risk of cancer in primary sclerosing cholangitis","volume":"50","author":"Claessen","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1478-3231.2011.02614.x","article-title":"Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort","volume":"32","author":"Lindkvist","year":"2012","journal-title":"Liver Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Catanzaro, E., Gringeri, E., Burra, P., and Gambato, M. (2023). Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies. Cancers, 15.","DOI":"10.3390\/cancers15204947"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.28529","article-title":"Aspirin use and the risk of cholangiocarcinoma","volume":"64","author":"Choi","year":"2016","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100570","DOI":"10.18632\/oncotarget.20141","article-title":"Smoking and risk of cholangiocarcinoma: A systematic review and meta-analysis","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1615\/JEnvironPatholToxicolOncol.v20.i4.70","article-title":"Alpha-particle carcinogenesis in Thorotrast patients: Epidemiology, dosimetry, pathology, and molecular analysis","volume":"20","author":"Ishikawa","year":"2001","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/cco.2019.08.13","article-title":"Gallbladder cancer: Epidemiology and genetic risk associations","volume":"8","author":"Schmidt","year":"2019","journal-title":"Chin. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ijc.34755","article-title":"Association of aflatoxin with gallbladder cancer in a case-control study nested within a Chinese cohort","volume":"154","author":"Koshiol","year":"2024","journal-title":"Int. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/sajc.sajc_37_18","article-title":"Geographical pattern of carcinoma gallbladder in Bihar and its association with river Ganges and arsenic levels: Retrospective individual consecutive patient data from Regional Cancer Centre","volume":"7","author":"Madhawi","year":"2018","journal-title":"South Asian J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5114\/ceh.2019.85166","article-title":"Epidemiology of gallbladder cancer","volume":"5","author":"Rawla","year":"2019","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ijc.27777","article-title":"Risk factors for gallbladder cancer: A case-control study","volume":"132","author":"Jain","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1732","DOI":"10.1590\/0102-672020230002e1732","article-title":"Gallbladder polyps: Correlation and agreement between ultrasonographic and histopathological findings in a population with high incidence of gallbladder cancer","volume":"36","author":"Inzunza","year":"2023","journal-title":"Arq. Bras. Cir. Dig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5009\/gnl.2012.6.2.172","article-title":"Epidemiology of gallbladder disease: Cholelithiasis and cancer","volume":"6","author":"Stinton","year":"2012","journal-title":"Gut Liver"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/PAS.0b013e31822179cc","article-title":"Hyalinizing cholecystitis and associated carcinomas: Clinicopathologic analysis of a distinctive variant of cholecystitis with porcelain-like features and accompanying diagnostically challenging carcinomas","volume":"35","author":"Patel","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11605-013-2170-0","article-title":"Porcelain gallbladder: A benign process or concern for malignancy?","volume":"17","author":"Schnelldorfer","year":"2013","journal-title":"J. Gastrointest. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.dld.2010.05.002","article-title":"Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the \u201cCholangiocarcinoma\u201d committee of the Italian Association for the Study of Liver disease","volume":"43","author":"Alvaro","year":"2011","journal-title":"Dig. Liver Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12885-015-1475-7","article-title":"Cohort profile: Cholangiocarcinoma screening and care program (CASCAP)","volume":"15","author":"Khuntikeo","year":"2015","journal-title":"BMC Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1259\/bjr\/21653786","article-title":"Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: Correlation with pathological examination","volume":"85","author":"Xu","year":"2012","journal-title":"Br. J. Radiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0034-1399147","article-title":"CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients\u2014Early or late washout matters: A subanalysis of the DEGUM multicenter trial","volume":"36","author":"Wildner","year":"2015","journal-title":"Ultraschall. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21037\/hbsn.2016.12.10","article-title":"Multimodality imaging of intrahepatic cholangiocarcinoma","volume":"6","author":"Ghasabeh","year":"2017","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/RCT.0b013e3181d34532","article-title":"Evaluation of biliary malignancies using multidetector-row computed tomography","volume":"34","author":"Kim","year":"2010","journal-title":"J. Comput. Assist. Tomogr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s002610000079","article-title":"Intrahepatic peripheral cholangiocarcinoma: CT evaluation","volume":"25","author":"Valls","year":"2000","journal-title":"Abdom Imaging"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2013.02.013","article-title":"Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis","volume":"58","author":"Iavarone","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_65","first-page":"153","article-title":"Hepatocellular carcinoma: MRI and CT examination","volume":"9","author":"Szklaruk","year":"2007","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/gastro\/gou057","article-title":"Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: A systematic review and meta-analysis","volume":"3","author":"Navaneethan","year":"2015","journal-title":"Gastroenterol. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.gie.2014.09.017","article-title":"Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: A systematic review and meta-analysis","volume":"81","author":"Navaneethan","year":"2015","journal-title":"Gastrointest. Endosc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.gie.2015.04.030","article-title":"Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: A systematic review","volume":"82","author":"Navaneethan","year":"2015","journal-title":"Gastrointest. Endosc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jmri.24810","article-title":"MRI of cholangiocarcinoma","volume":"42","author":"Jhaveri","year":"2015","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jhep.2019.01.038","article-title":"(18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis","volume":"71","author":"Lamarca","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1572-0241.2000.01685.x","article-title":"The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis","volume":"95","author":"Patel","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1055\/a-1589-7638","article-title":"S3-Leitlinie: Diagnostik und Therapie bili\u00e4rer Karzinome","volume":"60","author":"Bitzer","year":"2022","journal-title":"Z. Gastroenterol."},{"key":"ref_73","first-page":"173","article-title":"Non-Coding RNA in Cholangiocarcinoma: An Update","volume":"28","author":"Li","year":"2023","journal-title":"FBL"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"69995","DOI":"10.18632\/oncotarget.19547","article-title":"The diagnostic\/prognostic potential and molecular functions of long non-coding RNAs in the exosomes derived from the bile of human cholangiocarcinoma","volume":"8","author":"Ge","year":"2017","journal-title":"Oncotarget"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"BSR20181573","DOI":"10.1042\/BSR20181573","article-title":"Down-regulation of lncRNA-NEF indicates poor prognosis in intrahepatic cholangiocarcinoma","volume":"39","author":"Liang","year":"2019","journal-title":"Biosci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.7150\/ijbs.66224","article-title":"YY1-induced DLEU1\/miR-149-5p Promotes Malignant Biological Behavior of Cholangiocarcinoma through Upregulating YAP1\/TEAD2\/SOX2","volume":"18","author":"Li","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/hep.31493","article-title":"A Circular RNA, Cholangiocarcinoma-Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers","volume":"73","author":"Xu","year":"2021","journal-title":"Hepatology"},{"key":"ref_78","first-page":"365","article-title":"A novel prognostic biomarker for cholangiocarcinoma: circRNA Cdr1as","volume":"22","author":"Jiang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"509","DOI":"10.18632\/aging.203828","article-title":"PSMA3-AS1 induced by transcription factor PAX5 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-376a-3p to up-regulate LAMC1","volume":"14","author":"Sun","year":"2022","journal-title":"Aging"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.18632\/aging.102680","article-title":"AR-induced ZEB1-AS1 represents poor prognosis in cholangiocarcinoma and facilitates tumor stemness, proliferation and invasion through mediating miR-133b\/HOXB8","volume":"12","author":"Jiang","year":"2020","journal-title":"Aging"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"16304","DOI":"10.18632\/aging.103660","article-title":"SP1-induced HOXD-AS1 promotes malignant progression of cholangiocarcinoma by regulating miR-520c-3p\/MYCN","volume":"12","author":"Li","year":"2020","journal-title":"Aging"},{"key":"ref_82","first-page":"178","article-title":"Knockdown of lncRNA SNHG20 Suppressed the Proliferation of Cholangiocarcinoma by Sponging miR-520f-3p","volume":"39","author":"Guan","year":"2024","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13577-020-00448-1","article-title":"Yin Yang 1-induced LINC00667 up-regulates pyruvate dehydrogenase kinase 1 to promote proliferation, migration and invasion of cholangiocarcinoma cells by sponging miR-200c-3p","volume":"34","author":"Li","year":"2021","journal-title":"Hum. Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s10620-021-06876-9","article-title":"Long Non-coding RNA FOXD2-AS1 Promotes Proliferation, Migration, and Invasion in Cholangiocarcinoma Through Regulating miR-760\/E2F3 Axis","volume":"67","author":"Hu","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"890605","DOI":"10.3389\/fcell.2022.890605","article-title":"Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma","volume":"10","author":"Wu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s00268-017-4453-1","article-title":"Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes","volume":"42","author":"Bagante","year":"2018","journal-title":"World J. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/bjs.10556","article-title":"Surgical resection for Bismuth type IV perihilar cholangiocarcinoma","volume":"105","author":"Ebata","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1245\/s10434-019-07968-7","article-title":"The MEGNA Score and Preoperative Anemia are Major Prognostic Factors After Resection in the German Intrahepatic Cholangiocarcinoma Cohort","volume":"27","author":"Schnitzbauer","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"(2023). EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J. Hepatol., 79, 181\u2013208.","DOI":"10.1016\/j.jhep.2023.03.010"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): A multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients with Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_97","first-page":"S563","article-title":"53MO Nal-IRI and 5-FU\/LV compared to 5-FU\/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC\u2013AIO-HEP-0116)","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11605-007-0335-4","article-title":"Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period","volume":"12","author":"Becker","year":"2008","journal-title":"J. Gastrointest. Surg."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Kim","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1245\/s10434-020-09001-8","article-title":"Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma","volume":"28","author":"Vugts","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jamcollsurg.2012.05.025","article-title":"The Blumgart preoperative staging system for hilar cholangiocarcinoma: Analysis of resectability and outcomes in 380 patients","volume":"215","author":"Matsuo","year":"2012","journal-title":"J. Am. Coll. Surg."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Farha, N., Dima, D., Ullah, F., and Kamath, S. (2023). Precision Oncology Targets in Biliary Tract Cancer. Cancers, 15.","DOI":"10.3390\/cancers15072105"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Valery, M., Vasseur, D., Fachinetti, F., Boil\u00e8ve, A., Smolenschi, C., Tarabay, A., Antoun, L., Perret, A., Fuerea, A., and Pudlarz, T. (2023). Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments. Cancers, 15.","DOI":"10.3390\/cancers15184446"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"46750","DOI":"10.18632\/oncotarget.8775","article-title":"The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets","volume":"7","author":"Chong","year":"2016","journal-title":"Oncotarget"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"102170","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"G\u00f6n\u00fcl Geyik, \u00d6., Anichini, G., Ulukaya, E., Marra, F., and Raggi, C. (2022). DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. Cells, 11.","DOI":"10.3390\/cells11091463"},{"key":"ref_110","first-page":"492","article-title":"Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy","volume":"36","author":"Kabbara","year":"2022","journal-title":"Oncology"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Dai, S., Zhou, Z., Chen, Z., Xu, G., and Chen, Y. (2019). Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. Cells, 8.","DOI":"10.3390\/cells8060614"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The Fibroblast Growth Factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-med-042921-024707","article-title":"FGFR2 Inhibition in Cholangiocarcinoma","volume":"74","author":"Vogel","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR Genetic Aberrations: A Unique Clinical Phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e0231877","DOI":"10.1371\/journal.pone.0231877","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS ONE"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e2100414","DOI":"10.1200\/PO.21.00414","article-title":"Progression-Free Survival in Patients with Cholangiocarcinoma with or without FGF\/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response","volume":"6","author":"Bibeau","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2022.40.16_suppl.4009","article-title":"Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements","volume":"40","author":"Goyal","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e0162594","DOI":"10.1371\/journal.pone.0162594","article-title":"Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation","volume":"11","author":"Hall","year":"2016","journal-title":"PLoS ONE"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.1016\/j.annonc.2022.07.087","article-title":"Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications","volume":"33","author":"Borad","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2019.37.15_suppl.4117","article-title":"Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations","volume":"37","author":"Park","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s10637-021-01170-x","article-title":"A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma","volume":"40","author":"Ahn","year":"2022","journal-title":"Investig. New Drugs"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-18-1959","article-title":"A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations","volume":"25","author":"Voss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1200\/JCO.2020.38.15_suppl.3603","article-title":"Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion","volume":"38","author":"Cleary","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1200\/JCO.2023.41.4_suppl.539","article-title":"Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis","volume":"41","author":"Javle","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MOG.0000000000000050","article-title":"Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma","volume":"30","author":"Grassian","year":"2014","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.humpath.2011.12.007","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma","volume":"43","author":"Kipp","year":"2012","journal-title":"Hum. Pathol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"100356","DOI":"10.1016\/j.ctarc.2021.100356","article-title":"IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2017.03.026","article-title":"Emerging molecular therapeutic targets for cholangiocarcinoma","volume":"67","author":"Rizvi","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"TPS350","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS350","article-title":"A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors","volume":"39","author":"Pauff","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Simile, M.M., Bagella, P., Vidili, G., Spanu, A., Manetti, R., Seddaiu, M.A., Babudieri, S., Madeddu, G., Serra, P.A., and Altana, M. (2019). Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. Medicina, 55.","DOI":"10.3390\/medicina55020042"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/tgh.2018.07.02","article-title":"Precision medicine in cholangiocarcinoma","volume":"3","author":"Pellino","year":"2018","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: A potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): A multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2022.40.4_suppl.439","article-title":"Varlitinib in combination with gemcitabine and cisplatin for treatment-na\u00efve advanced biliary tract cancer","volume":"40","author":"Oh","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"100314","DOI":"10.1016\/j.esmoop.2021.100314","article-title":"Varlitinib plus capecitabine in second-line advanced biliary tract cancer: A randomized, phase II study (TreeTopp)","volume":"7","author":"Javle","year":"2022","journal-title":"ESMO Open"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2147\/OTT.S297643","article-title":"Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview","volume":"14","author":"Yang","year":"2021","journal-title":"OncoTargets Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000513847","article-title":"Targeting HER2 in Biliary Tract Carcinomas: Challenges and Opportunities","volume":"44","author":"Koeberle","year":"2021","journal-title":"Oncol. Res. Treat."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: A multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"12071","DOI":"10.1002\/cam4.5893","article-title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma","volume":"12","author":"Lolkema","year":"2023","journal-title":"Cancer Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.23.01193","article-title":"Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Na\u00efve Human Epidermal Growth Factor Receptor 2\u2013Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB)","volume":"42","author":"Ostwal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2005.05.3579","article-title":"Phase II Study of Erlotinib in Patients with Advanced Biliary Cancer","volume":"24","author":"Philip","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.29778","article-title":"Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)","volume":"122","author":"Leone","year":"2016","journal-title":"Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): A randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/bjc.2013.801","article-title":"S0941: A phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma","volume":"110","author":"Rankin","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11523-018-0590-1","article-title":"TRK Inhibition: A New Tumor-Agnostic Treatment Strategy","volume":"13","author":"Kummar","year":"2018","journal-title":"Target Oncol"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Scaltriti","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1093\/oncolo\/oyad075","article-title":"A Two-Step Diagnostic Approach for NTRK Gene Fusion Detection in Biliary Tract and Pancreatic Adenocarcinomas","volume":"28","author":"Demols","year":"2023","journal-title":"Oncologist"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in Patients with Tumors with BRAF(V600E) Mutations: Results of the NCI-MATCH Trial Subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: The phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e15038","DOI":"10.1200\/JCO.2021.39.15_suppl.e15038","article-title":"Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts)","volume":"39","author":"Rose","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"102447","DOI":"10.1016\/j.eclinm.2024.102447","article-title":"Dabrafenib and trametinib administration in patients with BRAF V600E\/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): A multicentre, open-label, and single-arm phase II trial","volume":"69","author":"Shimoi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ctrv.2018.09.002","article-title":"Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair","volume":"70","author":"Lamarca","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2019.07.022","article-title":"Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker","volume":"120","author":"Chae","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: The Catalogue Of Somatic Mutations In Cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"Bailey","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/cco.2020.02.02","article-title":"Biliary tract cancer and genomic alterations in homologous recombinant deficiency: Exploiting synthetic lethality with PARP inhibitors","volume":"9","author":"Ahn","year":"2020","journal-title":"Chin. Clin. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Ricci, A.D., Rizzo, A., Bonucci, C., Tober, N., Palloni, A., Mollica, V., Maggio, I., Deserti, M., Tavolari, S., and Brandi, G. (2020). PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. Medicines, 7.","DOI":"10.3390\/medicines7090054"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Bezrookove, V., Patino, J.M., Nosrati, M., Desprez, P.Y., McAllister, S., Soroceanu, L., Baron, A., Osorio, R., Kashani-Sabet, M., and Dar, A.A. (2021). Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress. Cancers, 13.","DOI":"10.3390\/cancers13174405"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.2022.40.16_suppl.3122","article-title":"Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms","volume":"40","author":"George","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2016-0415","article-title":"Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study","volume":"22","author":"Golan","year":"2017","journal-title":"Oncologist"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"Of4","DOI":"10.1158\/2159-8290.CD-NB2017-026","article-title":"IDH-Mutant Tumors Vulnerable to PARP Inhibition","volume":"7","author":"Leslie","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","article-title":"A WEE1 family business: Regulation of mitosis, cancer progression, and therapeutic target","volume":"13","author":"Cerchione","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4143\/crt.2020.080","article-title":"Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer","volume":"52","author":"Nam","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4143\/crt.2021.473","article-title":"Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer","volume":"54","author":"Seo","year":"2022","journal-title":"Cancer Res. Treat."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-21-0329","article-title":"Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors","volume":"27","author":"Takebe","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1200\/JCO.2018.36.15_suppl.2579","article-title":"A phase 1b dose-escalation study of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor, in combination with cisplatin in patients with advanced cancer","volume":"36","author":"Patel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/1751-2980.13168","article-title":"Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives","volume":"24","author":"Li","year":"2023","journal-title":"J. Dig. Dis."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1021\/bi00385a042","article-title":"Characterization of polymers of adenosine diphosphate ribose generated in vitro and in vivo","volume":"26","author":"Jacobson","year":"1987","journal-title":"Biochemistry"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1158\/1078-0432.CCR-19-0127","article-title":"Alterations in DNA Damage Repair Genes in Primary Liver Cancer","volume":"25","author":"Lin","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000529919","article-title":"Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation","volume":"46","author":"Costa","year":"2023","journal-title":"Oncol. Res. Treat."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.21037\/atm-21-3681","article-title":"Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: A case report","volume":"9","author":"Li","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.2147\/OTT.S176914","article-title":"Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: A case report","volume":"11","author":"Cheng","year":"2018","journal-title":"OncoTargets Ther."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.2147\/OTT.S317514","article-title":"Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation","volume":"14","author":"Su","year":"2021","journal-title":"OncoTargets Ther."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"933943","DOI":"10.3389\/fonc.2022.933943","article-title":"Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate","volume":"12","author":"Zhou","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.2147\/OTT.S250454","article-title":"Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report","volume":"13","author":"Xiong","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejim.2019.10.030","article-title":"Identification of EML4-ALK fusion in a sporadic case of cholangiocarcinoma","volume":"71","author":"Trombetta","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.21037\/atm-20-1007","article-title":"Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: A case report","volume":"8","author":"Zhou","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e15124","DOI":"10.1200\/jco.2015.33.15_suppl.e15124","article-title":"A phase II and biomarker study of cabozantinib (XL-184) in patients (pts) with advanced cholangiocarcinoma (CCA)","volume":"33","author":"Goyal","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/annonc\/mdu157","article-title":"A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors","volume":"25","author":"Pant","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1634\/theoncologist.2020-0535","article-title":"Identification of a Novel EHBP1-MET Fusion in an Intrahepatic Cholangiocarcinoma Responding to Crizotinib","volume":"25","author":"Yu","year":"2020","journal-title":"Oncologist"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Wang, S., Yadav, A.K., Han, J.Y., Ahn, K.S., and Jang, B.C. (2022). Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9\/3, DR-4, STAT-3\/STAT-5, Mcl-1, eIF-2\u03b1, and HIF-1\u03b1. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116353"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"434","DOI":"10.37349\/etat.2021.00055","article-title":"Targeting protein kinase CK2 in the treatment of cholangiocarcinoma","volume":"2","author":"Jayaraman","year":"2021","journal-title":"Explor. Target. Antitumor. Ther."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.2021.39.3_suppl.312","article-title":"Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib\/II study","volume":"39","author":"Borad","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1038\/s41467-018-07341-4","article-title":"RET rearrangements are actionable alterations in breast cancer","volume":"9","author":"Paratala","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-0034-1394144","article-title":"Cholangiocarcinoma: Molecular pathways and therapeutic opportunities","volume":"34","author":"Rizvi","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/cncr.33364","article-title":"Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers","volume":"127","author":"Tan","year":"2021","journal-title":"Cancer"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.21.01648","article-title":"Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F","volume":"40","author":"Damodaran","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.18632\/oncotarget.27251","article-title":"Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: A phase 2, open-label, single-arm study","volume":"10","author":"Taylor","year":"2019","journal-title":"Oncotarget"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"12122","DOI":"10.1038\/srep12122","article-title":"Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer","volume":"5","author":"Ahn","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/annonc\/mdu175","article-title":"Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: A phase II ITMO study","volume":"25","author":"Buzzoni","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12885-017-3196-6","article-title":"Prospective phase II trial of everolimus in PIK3CA amplification\/mutation and\/or PTEN loss patients with advanced solid tumors refractory to standard therapy","volume":"17","author":"Kim","year":"2017","journal-title":"BMC Cancer"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.3748\/wjg.v23.i23.4311","article-title":"Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation","volume":"23","author":"Bian","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"110851","DOI":"10.1016\/j.biopha.2020.110851","article-title":"WNT\/\u03b2-catenin signaling in the development of liver cancers","volume":"132","author":"He","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41575-018-0075-9","article-title":"Wnt-\u03b2-catenin signalling in liver development, health and disease","volume":"16","author":"Perugorria","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Wang, W., Smits, R., Hao, H., and He, C. (2019). Wnt\/\u03b2-Catenin Signaling in Liver Cancers. Cancers, 11.","DOI":"10.3390\/cancers11070926"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"BSR20193353","DOI":"10.1042\/BSR20193353","article-title":"Wnt\/\u03b2-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma","volume":"40","author":"Zhang","year":"2020","journal-title":"Biosci. Rep."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"70378","DOI":"10.18632\/oncotarget.11859","article-title":"Dickkopf-1 expression is associated with tumorigenity and lymphatic metastasis in human hilar cholangiocarcinoma","volume":"7","author":"Shi","year":"2016","journal-title":"Oncotarget"},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Kim, S.Y., Lee, H.S., Bang, S.M., Han, D.H., Hwang, H.K., Choi, G.H., Chung, M.J., and Kim, S.U. (2021). Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma. Cancers, 13.","DOI":"10.3390\/cancers13081828"},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Arsenijevic, T., Coulonval, K., Rasp\u00e9, E., Demols, A., Roger, P.P., and Van Laethem, J.L. (2023). CDK4\/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges. Cancers, 15.","DOI":"10.3390\/cancers15030968"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"e2100547","DOI":"10.1200\/PO.21.00547","article-title":"Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients with Cancer","volume":"6","author":"Thein","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"425082","DOI":"10.1200\/JCO.2023.41.36_suppl.425082","article-title":"KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Pant","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","article-title":"Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers","volume":"29","author":"Phelps","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1200\/JCO.2018.36.15_suppl.4084","article-title":"Selumetinib (Sel) and cisplatin\/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial","volume":"36","author":"Doherty","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/bjc.2017.119","article-title":"The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma","volume":"116","author":"Shroff","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41416-019-0523-5","article-title":"Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS\/RAF\/MEK\/ERK pathway: Phase Ib study","volume":"121","author":"Kim","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_238","first-page":"525","article-title":"Angiogenesis in cholangiocellular carcinoma: Expression of vascular endothelial growth factor, angiopoietin-1\/2, thrombospondin-1 and clinicopathological significance","volume":"15","author":"Tang","year":"2006","journal-title":"Oncol. Rep."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(09)70333-X","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: A phase 2 study","volume":"11","author":"Zhu","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10637-017-0492-6","article-title":"Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers","volume":"36","author":"Dior","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3748\/wjg.v21.i7.2096","article-title":"FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma","volume":"21","author":"Lorgis","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/COC.0000000000000347","article-title":"A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer","volume":"41","author":"Iyer","year":"2018","journal-title":"Am J. Clin. Oncol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2010.28.4075","article-title":"Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: A phase II Consortium study","volume":"28","author":"Lubner","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ijc.33509","article-title":"Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations","volume":"149","author":"Amin","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1158\/1078-0432.CCR-21-3548","article-title":"Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(19)30458-9","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): A multicohort, non-randomised, open-label, phase 1a\/b trial","volume":"20","author":"Herbst","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(21)00409-5","article-title":"Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study","volume":"22","author":"Valle","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.clcc.2020.05.007","article-title":"MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine with Aflibercept in Patients with Gastrointestinal and Breast Cancer","volume":"19","author":"Camera","year":"2020","journal-title":"Clin Colorectal Cancer"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial","volume":"102","author":"Bengala","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s10637-011-9719-0","article-title":"SWOG 0514: A phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","volume":"30","author":"Rankin","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/j.ejca.2014.09.013","article-title":"Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme","volume":"50","author":"Moehler","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/bjc.2013.432","article-title":"A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas","volume":"109","author":"Lee","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"785535","DOI":"10.3389\/fonc.2022.785535","article-title":"Lenvatinib Beyond First-Line Therapy in Patients with Advanced Biliary Tract Carcinoma","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"e16163","DOI":"10.1200\/JCO.2021.39.15_suppl.e16163","article-title":"Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma","volume":"39","author":"Shi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"414","DOI":"10.21037\/hbsn-20-338","article-title":"Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma","volume":"9","author":"Lin","year":"2020","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO.2021.39.3_suppl.321","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study","volume":"39","author":"Villanueva","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2217\/fon-2020-0758","article-title":"Systemic therapy of advanced hepatocellular carcinoma","volume":"17","author":"Galle","year":"2021","journal-title":"Future Oncol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.31872","article-title":"A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma","volume":"125","author":"Sun","year":"2019","journal-title":"Cancer"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1200\/JCO.2019.37.15_suppl.4083","article-title":"Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC)","volume":"37","author":"Kim","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.annonc.2020.05.018","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial","volume":"31","author":"Demols","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1358\/dot.2010.46.9.1516989","article-title":"Vandetanib: An overview of its clinical development in NSCLC and other tumors","volume":"46","author":"Morabito","year":"2010","journal-title":"Drugs Today"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s10637-015-0316-5","article-title":"Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers","volume":"34","author":"Kessler","year":"2016","journal-title":"Investig. New Drugs"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdu576","article-title":"A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: The VanGogh study","volume":"26","author":"Santoro","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): A randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/jco.2015.33.3_suppl.343","article-title":"Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma (SUN-CK phase II trial): Safety, efficacy, and updated translational results","volume":"33","author":"Neuzillet","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_266","first-page":"3711","article-title":"Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 Cases","volume":"37","author":"OKANO","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1002\/cncr.33803","article-title":"A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"e16170","DOI":"10.1200\/JCO.2023.41.16_suppl.e16170","article-title":"The clinical efficacy and safety of sintilimab plus anlotinib for unresectable intrahepatic cholangiocarcinoma (ICC): A prospective, single-arm phase II study","volume":"41","author":"Cheng","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.32548","article-title":"Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis","volume":"77","author":"Zhou","year":"2023","journal-title":"Hepatology"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1200\/JCO.2021.39.15_suppl.2565","article-title":"Pembrolizumab in microsatellite instability high (MSI-H)\/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study","volume":"39","author":"Maio","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"Boil\u00e8ve, A., Hilmi, M., Smolenschi, C., Ducreux, M., Hollebecque, A., and Malka, D. (2021). Immunotherapy in Advanced Biliary Tract Cancers. Cancers, 13.","DOI":"10.3390\/cancers13071569"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2018.36.4_suppl.263","article-title":"Variations in DNA repair genomic alterations and tumor mutation burden in biliary tract cancer (BTC) subtypes","volume":"36","author":"Ali","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Oh","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1200\/JCO.2019.37.15_suppl.4082","article-title":"Efficacy and safety of pembrolizumab in patients with PD-L1 positive advanced biliary tract cancer (BTC): A prospective cohort study","volume":"37","author":"Kang","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2147\/OTT.S195537","article-title":"Efficacy and safety of nivolumab for metastatic biliary tract cancer","volume":"12","author":"Gou","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: A non-randomised, multicentre, open-label, phase 1 study","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A Phase 2 Multi-institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract Cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2019.37.4_suppl.387","article-title":"Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC)","volume":"37","author":"Ioka","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_283","first-page":"S563","article-title":"52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-na\u00efve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1093\/oncolo\/oyab073","article-title":"A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma","volume":"27","author":"Monge","year":"2022","journal-title":"Oncologist"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/cncr.34394","article-title":"A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01","volume":"128","author":"Sahai","year":"2022","journal-title":"Cancer"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2020.38.4_suppl.535","article-title":"SHR-1210 combined with GEMOX as first-line treatment in patients with advanced biliary tract cancer","volume":"38","author":"Chen","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"e16170","DOI":"10.1200\/JCO.2021.39.15_suppl.e16170","article-title":"Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: Update analytic results of an open-label phase II clinical study (JS001-ZS-BC001)","volume":"39","author":"Li","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.2023.41.4_suppl.491","article-title":"IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer","volume":"41","author":"Ren","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"S268","DOI":"10.1016\/j.annonc.2020.08.051","article-title":"73P Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with pretreated biliary tract cancer","volume":"31","author":"Yoo","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_293","first-page":"3575","article-title":"MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer","volume":"25","author":"Yamamoto","year":"2005","journal-title":"Anticancer Res."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/CJI.0b013e3181fb65b9","article-title":"Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer","volume":"34","author":"Kaida","year":"2011","journal-title":"J. Immunother."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1479-5876-12-61","article-title":"Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer","volume":"12","author":"Aruga","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/1078-0432.CCR-12-3592","article-title":"Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer","volume":"19","author":"Aruga","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/cas.13193","article-title":"A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer","volume":"108","author":"Shirahama","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12943-017-0587-x","article-title":"BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma","volume":"16","author":"Parasramka","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41419-020-03346-4","article-title":"Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p\/BCL9L axis","volume":"12","author":"Lu","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"e23138","DOI":"10.1002\/jcla.23138","article-title":"Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma","volume":"34","author":"Lu","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-04-3586","article-title":"Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents","volume":"65","author":"Jimeno","year":"2005","journal-title":"Cancer Res."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1517\/13543784.13.12.1569","article-title":"The therapeutic potential of agents targeting the type I insulin-like growth factor receptor","volume":"13","author":"Zhang","year":"2004","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1535-7163.MCT-06-0080","article-title":"Disrupting insulin-like growth factor signaling as a potential cancer therapy","volume":"6","author":"Sachdev","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000151541","article-title":"Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines","volume":"54","author":"Namwat","year":"2008","journal-title":"Chemotherapy"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00280-011-1558-3","article-title":"Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients","volume":"68","author":"Hwang","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1158\/1078-0432.CCR-07-1381","article-title":"Enhanced expression of RAD51 associating protein-1 is involved in the growth of intrahepatic cholangiocarcinoma cells","volume":"14","author":"Obama","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0168-8278(01)00106-4","article-title":"Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma","volume":"35","author":"Momoi","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-021-02235-8","article-title":"Macrophages-aPKC(\u0269)-CCL5 Feedback Loop Modulates the Progression and Chemoresistance in Cholangiocarcinoma","volume":"41","author":"Yang","year":"2022","journal-title":"J Exp Clin. Cancer Res."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/9\/1690\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:34:10Z","timestamp":1760106850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/9\/1690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":310,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["cancers16091690"],"URL":"https:\/\/doi.org\/10.3390\/cancers16091690","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]}}}